The YES–YAP/TAZ signaling pathway is dysregulated in a subset of patients with HCC, predicting increased tumor burden and poor outcome (Driskill and Pan, 2021; Garmendia et al., 2022; Lapouge and Meloche, 2023; Shi et al., 2023; Zhang and Zhou, 2019). The gene discussed is YES1; the disease is hepatocellular carcinoma.